HOWL

Werewolf Therapeutics, Inc.

Werewolf Therapeutics, Inc. (HOWL) has 10 SEC Form 4 filings (32 transaction rows) in the rolling window, disclosed by 2 distinct insiders. Most recent filing: Jul 8, 2026.

The most active filer is Director EVNIN LUKE with 18 filings. Insiders have net sold $1.5M over the trailing 6 months.

  • Industry:Biotechnology
  • CEO:Daniel J. Hicklin
  • Employees:46
  • HQ:Watertown, MA, US
  • IPO:2021-04-30

Insider Buying

$0

reported purchases (SEC code P)

Insider Selling

$1.5M

reported sales (SEC code S)

Unique Insiders

2

in the rolling window

Market Cap

$16.5M

latest known value

Source
Sale$11KJul 8SEC ↗
Sale$33KJul 8SEC ↗
Sale$47KJun 29SEC ↗
Sale$146KJun 22SEC ↗
Sale$137KJun 12SEC ↗
Sale$17KJun 12SEC ↗
Sale$100KJun 12SEC ↗
Sale$38KJun 3SEC ↗
Sale$13KJun 3SEC ↗
Sale$12KJun 3SEC ↗
Sale$39KMay 29SEC ↗
Sale$13KMay 29SEC ↗
Sale$15KMay 29SEC ↗
Sale$214KMay 12SEC ↗
Sale$23KMay 12SEC ↗
Sale$43KMay 12SEC ↗
Sale$267KMay 12SEC ↗
Sale$59KMay 12SEC ↗
Sale$65KMay 12SEC ↗
Sale$5KMay 7SEC ↗
Sale$10KMay 7SEC ↗
Sale$50KMay 7SEC ↗
EVNIN LUKEFirst filing
Sale$46KApr 29SEC ↗
EVNIN LUKEFirst filing
Sale$70KApr 29SEC ↗
EVNIN LUKEFirst filing
Sale$39KApr 29SEC ↗

Related companies

Werewolf Therapeutics, Inc. is in the Healthcare sector.